Skip to main content

Table 1 Patients’ characteristics at LM diagnosis

From: Development of a new method for identification and quantification in cerebrospinal fluid of malignant cells from breast carcinoma leptomeningeal metastasis

Number of inclusion

Age at BC diagnosis

BC characteristics

Age at LM diagnosis

Clinical symptoms

Biochemical CSF analysis

Cytological CSF analysis

Neuraxis MRI

03

56

Undifferenciated carcinoma, HPG 3, ER-, PR -, HER2-

60

Cognitive disorders

Proteinorachia: 0.24 g/l

Presence of malignant cells

LM involvement

Glycorachia: 2.7

Brain metastases

Chlorurorachia: 118

05

61

ILC, HPG 2, ER+, PR+, HER2-

61

Dizziness

Proteinorachia: 2.19 g/l

Presence of malignant cells

LM involvement

Glycorachia: 1.7

No brain metastases

Chlorurorachia: 124

06

53

Adenocarcinoma, HPG 2, ER+, PR+, HER2 -

74

None

Proteinorachia: 0.48 g/l

Presence of malignant cells

LM involvement

Glycorachia: 3.5

No brain metastases

Chlorurorachia: 123

09

42

Adenocarcinoma, HPG 2, ER+, PR +, HER2 -

60

Dizziness, deafness

Proteinorachia: 1.49 g/l

Presence of malignant cells

LM involvement

Glycorachia: 2.7

No brain metastases

Chlorurorachia: 116

10

47

IDC, HPG 2, ER+, PR+, HER2-

59

Visual disorders

Proteinorachia: 0.51 g/l

Presence of malignant cells

LM involvement

Glycorachia: 4.0

Brain metastases

Chlorurorachia: 120

11

41

ICL, HPG 3, ER+, PR -, HER2 +

45

Cauda equine syndrome

Proteinorachia: 7.08 g/l

Presence of malignant cells

LM involvement

Glycorachia: 2

Brain metastases

Chlorurorachia: 113

12

44

IDC, HPG 2, ER+, PR+, HER2 +

57

None

Proteinorachia: 0.28 g/l

Presence of malignant cells

LM involvement

Glycorachia: 4.9

Brain metastases

Chlorurorachia: 120

13

45

Undifferenciated carcinoma, HPG 3, ER+, PR+, HER2 -

50

Cauda equina syndrome

Proteinorachia: 5.80 g/l

Presence of malignant cells

LM involvement

Glycorachia: 3.6

Brain metastases

Chlorurorachia: 111

  1. LM Leptomeningeal Metastases, CSF Cerebro Spinal Fluid, TC Tumor Cells, ILC Invasive Lobular Carcinoma, IDC Invasive Ductal Carcinoma, HPG histoprognostic grade, ER Estrogen Receptors, PR Progesterone Receptors, HER2 Human Epidermal Growth Factor Receptor-2, TTF1 Thyroid Transcription Factor 1, EGFR Epidermal Growth Factor Receptor, CNS Central Nervous System, MRI Magnetic Resonance Imaging, IT IntraThecal.